Est. 2026Independent · Educational

Compound Chronicle

Investigations intocompounded care

Vol. ISeptember 2026 editionRankings · Investigations · Explainers

503A vs 503B Pharmacies: What the Difference Means for Patients

Avery Holm

Educational content — not medical advice.

The short answer: 503A pharmacies compound medications for individual patients based on a prescription and are overseen mainly by state boards of pharmacy. 503B outsourcing facilities voluntarily register with FDA, must follow federal manufacturing-quality rules (CGMP), are inspected by FDA on a risk-based schedule, and can supply health care facilities without patient-specific prescriptions. Neither lane’s drugs are FDA-approved.

Sources for this summary: [1], [2], [3], [4], [5]. Educational content, not medical advice.

Seen “503A” or “503B” on a pharmacy website, label, or clinic FAQ? Those are two sections of federal law describing two legal lanes for compounded drugs. This explainer maps who oversees each lane, whether a patient-specific prescription is required, and which quality rules apply. It doesn’t rank pharmacies or suggest either lane is the right choice for anyone.

What is drug compounding?

FDA describes compounding as a licensed pharmacist, a licensed physician, or (in an outsourcing facility) a person supervised by a licensed pharmacist combining, mixing, or altering drug ingredients to create a medication tailored to a patient’s needs [1]. FDA’s examples include a version made without a dye a patient is allergic to, or a liquid for someone who can’t swallow a tablet [2].

The key fact: compounded drugs are not FDA-approved. FDA does not review their safety, effectiveness, or quality before they are marketed [1]. That’s true in both lanes.

Where did “503A” and “503B” come from?

The names refer to Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), codified at 21 U.S.C. 353a and 353b [4][5].

  • Section 503A was added in 1997 [4]. It sets conditions under which drugs compounded by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, are exempt from the Act’s requirements for FDA approval, CGMP, and labeling with adequate directions for use [3][4].
  • Section 503B was created by the Drug Quality and Security Act (DQSA), H.R. 3204 of the 113th Congress, which became Public Law 113-54 on November 27, 2013 [6]. It established outsourcing facilities as a new, voluntary category of compounders [3][5]. The DQSA also removed 503A advertising provisions that had been found unconstitutional [3].

The backdrop was a public health emergency. In September 2012, CDC, with state and local health departments and FDA, began investigating a multistate outbreak of fungal meningitis and other infections among patients who received contaminated steroid injections from the New England Compounding Center in Framingham, Massachusetts [16]. CDC’s final count was 753 cases and 64 deaths across 20 states [16]. According to FDA, Congress passed the DQSA in response to that outbreak and other serious adverse events linked to poor-quality compounded drugs [3].

What is a 503A pharmacy?

This is the traditional compounding pharmacy. Under Section 503A, a drug qualifies for the law’s exemptions when it is compounded for an identified individual patient based on a valid prescription [4]. Compounding in “limited quantities” ahead of a prescription is allowed only when based on a history of valid prescriptions within an established relationship [4].

Who oversees it? State boards of pharmacy generally have primary responsibility for day-to-day oversight of pharmacies not registered as outsourcing facilities; FDA can also conduct surveillance and for-cause inspections [2]. State licensing can be specific. California, for example, requires a separate license to compound sterile drugs for injection, administration into the eye, or inhalation, and it inspects a location before issuing or renewing that license [14]. California’s current compounding regulations took effect October 1, 2025 [15].

What quality rules apply? 503A drugs are not subject to federal CGMP requirements [2][3]. The statute requires ingredients to meet applicable United States Pharmacopeia (USP) or National Formulary monographs where they exist, along with the USP chapter on pharmacy compounding, and requires certificates of analysis for bulk substances [4]. Federal provisions on insanitary conditions apply wherever compounding happens [2].

What is a 503B outsourcing facility?

The statute defines an outsourcing facility as a facility at one location that compounds sterile drugs, has elected to register as an outsourcing facility, and complies with all of Section 503B [5][8]. What sets this lane apart:

  • Voluntary FDA registration. A facility re-registers each year between October 1 and December 31 and pays an annual establishment fee [5][7].
  • CGMP. Outsourcing facilities must comply with current good manufacturing practice requirements [2][8]. FDA intends to issue outsourcing-facility-specific CGMP regulations; until then, its draft guidance describes how the requirements in 21 CFR parts 210 and 211 apply [17]. As of September 2026, FDA lists that guidance as a draft dated January 2020 [9].
  • FDA inspections on a risk-based schedule that weighs factors such as compliance history, recalls, and the inherent risk of the drugs compounded [2][5].
  • Product reporting at initial registration and every June and December [5][8].
  • Adverse-event reporting to FDA [5], following FDA guidance under 21 CFR 310.305 [10].
  • No patient-specific prescription required. An outsourcing facility “may or may not obtain prescriptions for identified individual patients” [5]. It can fill patient prescriptions or health care provider orders, such as a hospital’s, for office stock [3].

503B labels must include “This is a compounded drug” (or a comparable statement) and the facility’s contact information [5]. Registration does not make a product FDA-approved [1].

How do 503A and 503B compare side by side?

Status as of September 2026. Bracketed numbers refer to sources at the end.

503A pharmacy 503B outsourcing facility
Legal basis FD&C Act §503A (21 U.S.C. 353a), added 1997, amended by DQSA 2013 [3][4] FD&C Act §503B (21 U.S.C. 353b), created by DQSA 2013 [5][6]
Primary oversight State boards of pharmacy; FDA may inspect (surveillance, for-cause) [2] Primarily FDA [2]
Registration State-licensed pharmacy, federal facility, or licensed physician [4][14] Elects FDA registration; re-registers annually with fee [5][7]
Patient-specific prescription Required; limited advance compounding based on prescription history [4] Not required; may supply office stock [3][5]
Quality standard Exempt from federal CGMP; statutory USP/NF standards plus state rules [2][4] CGMP (21 CFR parts 210 and 211; FDA draft guidance) [8][9][17]
FDA inspections Surveillance and for-cause [2] Risk-based schedule [2][5]
Compounding ahead of prescriptions Only in limited quantities, based on prescription history [4] Permitted; may or may not obtain patient prescriptions [5]
Product reporting to FDA Section 503A has no product-reporting requirement like 503B’s [4] At registration, then every June and December [5][8]
Adverse-event reporting to FDA Not required by federal law for state-licensed pharmacies that are not outsourcing facilities [11] Required [5][10]
FDA-approved? No [1] No [1]

Why does the difference matter for patients?

The lanes differ in who inspects, which quality framework applies, and what gets reported to FDA. Those differences shape what you can verify. They don’t settle whether a compounded drug is right for a particular person; that’s a clinical question for a licensed clinician.

FDA notes that people getting compounded drugs through online pharmacies or telehealth platforms may not know which compounder made the drug or whether it is appropriately licensed [2]. Neutral questions to ask a provider:

  1. Which pharmacy or facility compounds this medication, and is it operating under 503A or 503B?
  2. Where is it licensed? For a 503A pharmacy, start with its home state board. If it ships from another state, ask whether it holds any license your state requires [14]. Our upcoming guide, How to Verify a Compounding Pharmacy’s License, walks through the lookup.
  3. If it’s a 503B facility, is it on FDA’s list? FDA’s registered outsourcing facility list carries an “Updated as of” date and shows each facility’s last FDA inspection date, whether a Form FDA 483 was issued, and any follow-up action. FDA notes a Form 483 is not a final agency determination, and the list omits state board actions [7].
  4. How do I report a problem? FDA encourages reporting adverse events or quality problems through MedWatch [11].

More background lives on our Compounding 101 hub.

How does this connect to compounded GLP-1s?

Much recent attention on compounding involves GLP-1 drugs such as semaglutide and tirzepatide. FDA stresses that compounded versions are not FDA-approved and haven’t undergone its review for safety, effectiveness, and quality [11]. Part of the legal story runs through FDA’s drug shortage list. One condition under which Section 503B allows compounding from a bulk substance is that the drug appears on that list, and for 503B, shortage status also affects whether a drug counts as “essentially a copy” [5].

Both lanes have “essentially a copy” limits on duplicating commercially available or approved drugs, with an exception for a change the prescriber determines makes a significant (503A) or clinical (503B) difference for an individual patient [4][5]; the Compounding 101 hub will cover those rules in depth. For GLP-1 shortage listings, policy changes, and court decisions, see The Shortage Era, 2022–2026: A Timeline of Compounded GLP-1 Rules.

Frequently asked questions

Is a 503B drug FDA-approved?

No. Compounded drugs are not FDA-approved [1][2]. Registration, CGMP, and FDA inspections [8] are not drug approval; Section 503B exempts qualifying compounded drugs from the approval requirement rather than granting approval [5].

Can a 503A pharmacy ship across state lines?

It depends on federal conditions and state licensing. Under Section 503A, a pharmacy in a state that has not signed a standard memorandum of understanding (MOU) with FDA may distribute compounded drugs out of state only up to 5 percent of its total prescription orders [4]. As of September 2026, FDA considers its October 2020 standard MOU suspended after a September 2021 court remand, and says it won’t begin enforcing the 5 percent limit until a final rule takes effect and an updated MOU is published [12]. The federal regulatory agenda targets a proposed rule for November 2026 [13]; target dates can change, so check FDA’s MOU page [12].

States also regulate pharmacies shipping into them. California, for example, requires a nonresident pharmacy shipping compounded sterile drugs into the state to hold both a nonresident pharmacy license and a separate nonresident sterile compounding license [14]. Our upcoming state-by-state guide will cover more states.

How do I check whether a facility is registered with FDA?

Search FDA’s “Registered Outsourcing Facilities” page [7]. A listing means FDA found the facility’s registration information complete and its annual fee paid [7]; it doesn’t make the facility’s products FDA-approved [1]. For state actions, FDA points readers to the state board of pharmacy where the facility is located [7].

Is a compounded drug the same as the brand-name drug?

No. Compounded drugs are not FDA-approved, and FDA says they aren’t the same as generics, which are FDA-approved and must establish therapeutic equivalence to the brand [2]. FDA lists claims that “the compounded drug is the same as an FDA-approved drug” among consumer red flags [11]. Our planned Myth vs Fact: “Compounded Means Generic” goes deeper.

Sources

All sources accessed 2026-09-28. Regulatory status described as of September 2026.

  1. U.S. Food and Drug Administration. “Human Drug Compounding.” https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding (accessed 2026-09-28)
  2. U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers (accessed 2026-09-28)
  3. U.S. Food and Drug Administration. “Human Drug Compounding Laws.” https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies (accessed 2026-09-28)
  4. 21 U.S.C. 353a, “Pharmacy compounding” (FD&C Act §503A). Office of the Law Revision Counsel, U.S. House of Representatives. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section353a&num=0&edition=prelim (accessed 2026-09-28)
  5. 21 U.S.C. 353b, “Outsourcing facilities” (FD&C Act §503B). Office of the Law Revision Counsel, U.S. House of Representatives. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section353b&num=0&edition=prelim (accessed 2026-09-28)
  6. Congress.gov. “H.R.3204 – Drug Quality and Security Act,” 113th Congress (2013-2014); became Public Law No. 113-54 on 11/27/2013. https://www.congress.gov/bill/113th-congress/house-bill/3204 (accessed 2026-09-28)
  7. U.S. Food and Drug Administration. “Registered Outsourcing Facilities” (page marked “Updated as of 9/24/2026” when accessed). https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities (accessed 2026-09-28)
  8. U.S. Food and Drug Administration. “Information for Outsourcing Facilities.” https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities (accessed 2026-09-28)
  9. U.S. Food and Drug Administration. “Current Good Manufacturing Practice—Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act” (revised draft guidance, January 2020; Docket FDA-2014-D-0779). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-guidance-human-drug-compounding-outsourcing-facilities-under (accessed 2026-09-28)
  10. U.S. Food and Drug Administration. “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act” (guidance, October 2015; Docket FDA-2014-D-2138). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adverse-event-reporting-outsourcing-facilities-under-section-503b-federal-food-drug-and-cosmetic-act (accessed 2026-09-28)
  11. U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (accessed 2026-09-28)
  12. U.S. Food and Drug Administration. “Memorandum of Understanding Addressing Certain Distributions of Compounded Drugs.” https://www.fda.gov/drugs/human-drug-compounding/memorandum-understanding-addressing-certain-distributions-compounded-drugs (accessed 2026-09-28)
  13. Office of Information and Regulatory Affairs, Unified Agenda. “Distribution of Compounded Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act,” RIN 0910-AI71 (NPRM timetable 11/00/2026). https://www.reginfo.gov/public/do/eAgendaViewRule?RIN=0910-AI71&pubId=202510 (accessed 2026-09-28)
  14. California State Board of Pharmacy. “Sterile Compounding/Nonresident Sterile Compounding/Hospital In-Patient Sterile Compounding Pharmacy License.” https://www.pharmacy.ca.gov/applicants/sicp.shtml (accessed 2026-09-28)
  15. California State Board of Pharmacy. “Approved Regulations” (Compounded Drug Preparations, effective October 1, 2025). https://www.pharmacy.ca.gov/laws_regs/approved_regs.shtml (accessed 2026-09-28)
  16. Centers for Disease Control and Prevention (archived page). “Multistate Outbreak of Fungal Meningitis and Other Infections.” https://archive.cdc.gov/www_cdc_gov/hai/outbreaks/meningitis.html (accessed 2026-09-28)
  17. Federal Register (FDA notice), “Current Good Manufacturing Practice—Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act; Draft Guidance for Industry; Availability,” Dec. 11, 2018, FR Doc. 2018-26724. https://www.federalregister.gov/documents/2018/12/11/2018-26724/current-good-manufacturing-practice-guidance-for-human-drug-compounding-outsourcing-facilities-under (accessed 2026-09-28)

Educational content only; not medical or legal advice. Compound Chronicle is an educational publisher, not a pharmacy or clinic. Avery Holm is an editorial pen name; this article was researched with AI assistance and goes through Compound Chronicle’s editorial review.

We may have a financial affiliation with some entities featured on this page.

Powered by